Arcutis Biotherapeutics
ARQT
ARQT
207 hedge funds and large institutions have $1.79B invested in Arcutis Biotherapeutics in 2024 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 59 increasing their positions, 65 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
207
Holders Change
+20
Holders Change %
+10.7%
% of All Funds
2.76%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
49
Increased
59
Reduced
65
Closed
28
Calls
$8.22M
Puts
$3.96M
Net Calls
+$4.25M
Net Calls Change
-$588K
Top Buyers
| 1 |
UBS Group
Zurich,
Switzerland
|
$38.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
$24.4M |
| 3 |
CM
Cercano Management
Bellevue,
Washington
|
$17.5M |
| 4 |
Millennium Management
New York
|
$32.2M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
$15.3M |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
$1.24M |
| 2 |
SC
Stempoint Capital
New York
|
$6.98M |
| 3 |
Franklin Resources
San Mateo,
California
|
$46.1M |
| 4 |
PA
Perceptive Advisors
New York
|
$0 |
| 5 |
JGC
J. Goldman & Co
New York
|
$8.53M |
